~25 spots leftby Jul 2026

Mindfulness App for Gynecologic Cancers

(MECCA Trial)

Recruiting in Palo Alto (17 mi)
SG
Overseen byShannon Grabosch, MD
Age: 18+
Sex: Female
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Recruiting
Sponsor: St. Louis University
Disqualifiers: Non-English speaking, No smartphone, others
No Placebo Group
Approved in 3 Jurisdictions

Trial Summary

What is the purpose of this trial?

Patients with endometrial cancer who will be undergoing surgery or patients with cervical cancer who will be treated with chemoradiation will be randomized to utilize the Headspace smartphone application or not prior to their anticipated treatment.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the treatment Headspace Mindfulness App for gynecologic cancers?

Research shows that mindfulness and meditation, like those offered by the Headspace app, can help reduce stress and improve mood and quality of life for cancer patients. A study on mobile app-delivered mindfulness training found it effective in improving quality of life among women with breast cancer, which may suggest similar benefits for those with gynecologic cancers.12345

Is the Headspace Mindfulness App safe for use in humans?

The research on mindfulness-based interventions, including those similar to the Headspace App, suggests they are generally safe for humans. Studies have shown that mindfulness can improve quality of life and reduce stress-related symptoms in cancer patients without significant safety concerns.678910

How does the mindfulness app treatment for gynecologic cancers differ from other treatments?

The mindfulness app treatment is unique because it uses a mobile app to deliver mindfulness training, which can improve quality of life and mental health for women with gynecologic cancers. Unlike traditional treatments that focus on physical symptoms, this approach targets psychological well-being and can be accessed conveniently from home.23111213

Research Team

SG

Shannon Grabosch, MD

Principal Investigator

St. Louis University

Eligibility Criteria

This trial is for English-speaking individuals newly diagnosed with endometrial cancer scheduled for surgery, or cervical cancer to be treated with chemoradiation. Participants must have access to a smartphone and not currently use the Headspace app.

Inclusion Criteria

You need to have a smartphone.
I am newly diagnosed with endometrial or cervical cancer and will undergo surgery or radiation.

Exclusion Criteria

No access to smartphone
Non-English speaking
You are currently using the Headspace app.

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks
1 visit (in-person)

Treatment

Patients with endometrial cancer undergo surgery or patients with cervical cancer receive chemoradiation, with randomization to use the Headspace app or not

6 weeks
3 visits (in-person)

Follow-up

Participants are monitored for opiate usage, quality of life, and complications post-treatment

4-6 weeks
1 visit (in-person), 1 phone call

Mindfulness Practice

Participants in the intervention group use the Headspace app for mindfulness exercises

3 months

Treatment Details

Interventions

  • Headspace Smartphone Application (Behavioral Intervention)
Trial OverviewThe study is testing if using the Headspace smartphone application can improve quality of life in patients undergoing treatment for endometrial or cervical cancer. Patients are randomly chosen to either use the app or not before their treatment starts.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: InterventionExperimental Treatment1 Intervention
Patients with endometrial cancer will be approached for participation at their pre-operative visit. Patients with cervical cancer will be approached at their pre-treatment visit. If the patient opts to participate, she will be randomized to utilize the Headspace smartphone application or not. She will be provided a three month gift subscription. Headspace will be downloaded to her smartphone and she will be instructed on use. Patients will be asked to complete a quality of life survey on the day of enrollment, the day of surgery (endometrial cancer) or first brachytherapy (cervical cancer) and at their post-treatment visit. The patient will receive one phone call prior to her post-treatment visit requesting she bring her bottle of opiate pills with her for counting. The number of pills used will be recorded. The number of Headspace sessions will be recorded. An anonymous survey will be provided for completion. The patient will be provided a gift card at completion.
Group II: ControlActive Control1 Intervention
Patients with endometrial cancer will be approached for participation at their pre-operative visit. Patients with cervical cancer will be approached at their pre-treatment visit. If the patient opts to participate, she will be randomized to utilize the Headspace smartphone application or not. All patients in the control group may choose to practice calming or mindfulness exercises of their own accord but will not be specifically instructed to seek out such resources as is our standard practice. Patients will be asked to complete a quality of life survey on the day of enrollment, the day of surgery (endometrial cancer) or first brachytherapy (cervical cancer) and at their post-treatment visit. The patient will receive one phone call prior to her post-treatment visit requesting she bring her bottle of opiate pills with her for counting. The number of pills used will be recorded. An anonymous survey will be provided for completion. The patient will be provided a gift card at completion.

Find a Clinic Near You

Who Is Running the Clinical Trial?

St. Louis University

Lead Sponsor

Trials
197
Recruited
41,400+
Dr. Laura Simpson profile image

Dr. Laura Simpson

St. Louis University

Chief Medical Officer since 2023

PhD in Molecular and Cellular Biology from Tulane University

Dr. Keith Vendola profile image

Dr. Keith Vendola

St. Louis University

Chief Executive Officer since 2023

PhD in Molecular Biology from Washington University in St. Louis

Findings from Research

A study involving 95 women with various cancer diagnoses showed that a self-hypnosis and self-care intervention significantly improved participants' quality of life, with 97.5% continuing to practice relaxation techniques after the program.
All components of the intervention, including group support and hypnosis exercises, were rated highly for their usefulness, indicating that a multicomponent approach may be effective in supporting cancer patients' self-care and well-being.
A Group Intervention Combining Self-Hypnosis and Self-Care in Oncology: Implementation in Daily Life and Perceived Usefulness.Grégoire, C., Faymonville, ME., Vanhaudenhuyse, A., et al.[2023]
Women with breast cancer who used a mobile app for mindfulness training reported significantly higher quality of life compared to those in the waitlist control group over an 8-week period.
The mindfulness training also led to increased dispositional mindfulness in participants, indicating that the app may help improve mental well-being alongside physical health after a breast cancer diagnosis.
Quality of life among women diagnosed with breast Cancer: A randomized waitlist controlled trial of commercially available mobile app-delivered mindfulness training.Rosen, KD., Paniagua, SM., Kazanis, W., et al.[2022]
The Gynecologic Survivorship Tool (GST) was successfully implemented for symptom management in women treated for gynecologic cancer, with a high completion rate of 71% from 1,405 patients over a year-long period.
The tool effectively identified common symptoms such as bowel problems and vaginal dryness, allowing healthcare teams to create targeted strategies for symptom relief, demonstrating its feasibility and efficiency in clinical settings.
Gynecologic Survivorship Tool: Development, Implementation, and Symptom Outcomes.Carter, J., Abu-Rustum, NR., Saban, S., et al.[2023]

References

A Group Intervention Combining Self-Hypnosis and Self-Care in Oncology: Implementation in Daily Life and Perceived Usefulness. [2023]
Quality of life among women diagnosed with breast Cancer: A randomized waitlist controlled trial of commercially available mobile app-delivered mindfulness training. [2022]
Mindfulness-based cognitive group therapy for women with breast and gynecologic cancer: a pilot study to determine effectiveness and feasibility. [2022]
Gynecologic Survivorship Tool: Development, Implementation, and Symptom Outcomes. [2023]
Mind-body interventions in oncology. [2021]
SafeSpace: what is the feasibility and acceptability of a codesigned virtual reality intervention, incorporating compassionate mind training, to support people undergoing cancer treatment in a clinical setting? [2022]
The ONE-MIND Study: Rationale and protocol for assessing the effects of ONlinE MINDfulness-based cancer recovery for the prevention of fatigue and other common side effects during chemotherapy. [2020]
A Mindfulness-Based Lifestyle Intervention for Obese, Inactive Endometrial Cancer Survivors: A Feasibility Study. [2023]
The effect of a contemplative self-healing program on quality of life in women with breast and gynecologic cancers. [2022]
10.United Statespubmed.ncbi.nlm.nih.gov
Evaluating the effectiveness of mindfulness alone compared to exercise and mindfulness on fatigue in women with gynaecology cancer (GEMS): Protocol for a randomised feasibility trial. [2023]
11.United Statespubmed.ncbi.nlm.nih.gov
Lessons learned: providing a mindfulness-based stress reduction program for low-income multiethnic women with abnormal pap smears. [2022]
12.United Statespubmed.ncbi.nlm.nih.gov
A brief mindfulness-based cognitive behavioral intervention improves sexual functioning versus wait-list control in women treated for gynecologic cancer. [2022]
Short-term effect of internet-delivered mindfulness-based stress reduction on mental health, self-efficacy, and body image among women with breast cancer during the COVID-19 pandemic. [2022]